To Evaluate the Efficacy and Safety of Collavant n2 in Individuals With Osteoarthritis of the Knee

A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Collavant n2 in Individuals With Osteoarthritis of the Knee

A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of Collavant n2 in individuals with osteoarthritis of the knee.

Study Overview

• Status: Completed
• Conditions: Osteoarthritis, Knee
• Intervention / Treatment: Other: Collavant n2 40 mg/day; Other: Glucosamine hydrochloride & Chondroitin sulfate; Other: Microcrystalline cellulose

• Study Type: Interventional
• Enrollment (Actual): 236
• Phase: Not Applicable

Contacts and Locations

Study Locations

• India
  • Gujarat
    • Ahmedabad, Gujarat, India, 380015
      • Amber Clinic
  • Maharashtra
    • Mumbai, Maharashtra, India, 400067
      • Ayush Nursing Home
    • Mumbai, Maharashtra, India, 400064
      • Diamond Hospital
    • Mumbai, Maharashtra, India, 400053
      • Prme Orthopedic Speciality
    • Nashik, Maharashtra, India, 422009
      • Life care Hospital
    • Palghar, Maharashtra, India, 401209
      • Care n Cure Multispeciality Hospital
    • Panvel, Maharashtra, India, 410206
      • Sparsh Hospital
    • Pune, Maharashtra, India, 411057
      • Lifepoint Multispeciality Hospital
    • Pune, Maharashtra, India, 411062
      • Imperial Multispecialty Hospital
    • Vasai, Maharashtra, India, 401208
      • Gayatri Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 36 years to 71 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Male and females ≥ 40 to ≤ 75 years suffering from knee joint pain for atleast 3 months before screening.
2. Body mass index (BMI) ≥ 18.5 and ≤ 29.9 kg/m2
3. Pain VAS for knee joint pain ≥ 5 and ≤ 7 cm on a 10 cm scale at screening.

4. Radiographic evidence of grade II/III knee OA based on the Kellgren and Lawrence (KL) radiographic entry criteria for OA - i Grade II: Antero-posterior weight-bearing knee radiograph demonstrates possible joint space narrowing (JSN) with definite osteophyte formation.

   ii Grade III: Antero-posterior weight-bearing knee radiograph demonstrates definite joint space narrowing, multiple osteophyte formations, some sclerosis, and possible deformity of bony ends.

5. LAI score of ≥ 6 - ≤10 at screening.

6. Willing to stop the restricted dietary supplements, home-based remedies, and any other form of topical products or medications for knee joint pain relief or any other reason for the entire study duration.

   (Note: only hot and cold fomentation will be allowed, and the participant has to record the daily frequency of fomentation in the diary. The hot/cold fomentation needs to be stopped 48 hours prior to all assessment visits.)

7. Willing to stop using rescue medication 48 hours prior to all assessment visits.
8. Using the western toilet at home and/or workplace.
9. Willingness to participate and comply with the study procedures and required visits.
10. Ability to understand and sign a written informed consent form, which must be completed before performing study-specific tasks.
11. Literate and have the ability to complete the study-based questionnaires and tasks.
12. Female participants of childbearing age must be willing to use the acceptable methods of contraception during the study.

Exclusion Criteria:

1 History of uncontrolled hypertension and/or systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg. 2 Fasting blood glucose (FBG) > 125 mg/dl. 3 Radiographic evidence of Grade I or Grade IV OA based on the KL radiographic criteria for osteoarthritis. 4 Any history of trauma, fractures, or surgery to the index joint. 5 Any planned surgery (diagnostic or therapeutic intervention) to the index joint during the participation in the study. 6 History of use of corticosteroid, disease modifying drugs, glucosamine, chondroitin, and intra-articular treatments including injections of corticosteroid or hyaluronic acid within 6 months of the screening visit and consumption of Omega-3 fatty acids or other joint health supplements within 15 days preceding the screening visit. 7 History of use of gabapentin within 6 weeks and/or methylcobalamin within 2 weeks prior to screening. 8 Known case of deformity of the knee joint or diagnosed on clinical examination during screening. 9 Known case of any joint disorder involving the index joint that includes but is not limited to known rheumatic or inflammatory conditions such as rheumatoid arthritis, osteomyelitis, osteoporosis, severe OA, and bone metastasis. 10 Known cases of gout and/or hyperuricemia (serum uric acid >440 μmol/L). 11 Other pathologic lesions on X-ray of the knee. 12 History of bleeding disorders (e.g., Haemophilia, Sickle cell anaemia, etc.).

13 Participants with abnormal levels of serum thyroid-stimulating hormone (TSH) (< 0.4 to > 4.2 mIU/L). 14 Any history or evidence of allergy to chicken, eggs, or protein products in the past. 15 Alcoholics or known drug dependents. (Alcoholism or heavy alcohol use is interpreted based on alcohol content consumed per day or week. It is defined as more than 4 drinks on any day or more than 14 drinks per week for men. For women, it is defined as more than 3 drinks on any day or more than 7 drinks per week. Standard alcoholic drink is roughly equivalent to 14 grams of pure alcohol, which is found in the following: i 12 ounces (Approx. 350 ml) of regular beer, which is usually about 5% alcohol ii 5 ounces (Approx. 150 ml) of wine, which is typically about 12% alcohol iii 1.5 ounces (Approx. 45 ml) of distilled spirits, which is about 40% alcohol) 16 History of smoking or currently smoking or using any form of smokeless tobacco. 17 Not willing to abstain from the use of NSAIDs (including low dose aspirin 50 mg/day for cardiovascular health). 18 Participation in a study of an investigational product within 90 days prior to the screening.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Collavant n2 40 mg/day; 2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days	Other: Collavant n2 40 mg/day; 2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
Active Comparator: Glucosamine hydrochloride & Chondroitin sulfate; 2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days	Other: Glucosamine hydrochloride & Chondroitin sulfate; 2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
Placebo Comparator: Microcrystalline cellulose; 2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days	Other: Microcrystalline cellulose; 2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Western Ontario and McMaster Universities Osteoarthritis Index Pain subscale	Knee joint pain as assessed by the change in the Western Ontario and McMaster Universities Osteoarthritis Index Pain subscale (WOMAC-P) score. the primary efficacy variable for the present study is the total WOMAC index score, the scores for each subscale will be summed up (Pain range: 0-20, Stiffness range: 0-8, and Physical function range: 0-68). Thus, the total WOMAC score will range from 0 - 96. The lowest the score is the good response and highest the score is extreme pain i.e. bad response.	Day 0, 7, 30, 60, 90, 120, 150, and 180

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Knee joint pain as assessed by the change in the Western Ontario and McMaster - Pain subscale score.	The first domain, WOMAC-P, comprises 5 questions evaluating the amount of pain due to OA in the index joint experienced by the participant. The WOMAC-P subscale score of 0 indicates 'No pain' and 4 indicates 'Extreme pain'.	Day 0, 7, 30, 60, 90, 120, 150, and 180
Knee joint stiffness as assessed by the change in the WOMAC - Stiffness subscale (WOMAC-S) score.	The domain, WOMAC-S, consists of 2 questions evaluating the amount of stiffness (resistance of the joint to movement characterized by difficulty in moving the joint along with pain and discomfort in the joint) experienced in the index joint. On the Likert scale, 0 indicates 'No stiffness' and 4 indicates 'Extreme stiffness'.	Day 0, 7, 30, 60, 90, 120, 150, and 180
Knee joint function as assessed by the change in the WOMAC - Physical function (WOMAC-PF) score.	The WOMAC-PF consists of 17 questions evaluating the degree of physical difficulty experienced in the index joint due to OA in the third domain. For WOMAC-PF, 0 indicates 'No difficulty' and 4 indicates 'Extreme difficulty'.	Day 0, 7, 30, 60, 90, 120, 150, and 180
Knee joint pain assessed by the change in the Visual Analogue Scale (VAS) score.	Point 0 indicates no pain and 10 indicates worst pain.	Day 0, 7, 30, 60, 90, 120, 150, and 180
Severity of osteoarthritis as assessed by the change in the Lequesne algofunctional index (LAI) score.	Higher scores indicate a worse joint condition and Lowest scores indicate agood joint condition	Day 0, 7, 30, 60, 90, 120, 150, and 180

Collaborators and Investigators

• Sponsor: Vedic Lifesciences Pvt. Ltd.
• Investigators: Study Director: Dr Shalini Srivastava, MD medicine, Vedic Lifesciences Pvt. Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): August 8, 2022
• Primary Completion (Actual): July 4, 2023
• Study Completion (Actual): July 4, 2023

Study Registration Dates

• First Submitted: July 22, 2022
• First Submitted That Met QC Criteria: July 25, 2022
• First Posted (Actual): July 26, 2022

Study Record Updates

• Last Update Posted (Estimated): September 6, 2023
• Last Update Submitted That Met QC Criteria: September 4, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Osteoarthritis, Knee
• Other Study ID Numbers: BI/210903/COLL/OA

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No